{
    "info": {
        "nct_id": "NCT06084416",
        "official_title": "A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects with Advanced High Grade Serous Ovarian Cancer",
        "inclusion_criteria": "* All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration\n* High Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer - histologically or cytologically confirmed; metastatic or unresectable; platinum resistant (defined as recurrence within 6 months of platinum containing therapy) or platinum refractory; prior bevacizumab treatment, or ineligible or intolerant to bevacizumab, or did not receive bevacizumab based on Investigator judgement; if germline and/or somatic BRCA1/2 mutation, previously treated with PARP-inhibitor or ineligible or intolerant.\n\nKey\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype\n* Endometrioid, clear cell, mucinous, sarcomatoid, low-grade/borderline ovarian tumor or mixed tumors containing any of the above histologies\n* Previously received KIF18A inhibitor\n* Current CNS metastases or leptomeningeal disease\n* Cardiac parameters: MI or stroke ≤ 6 months, unstable angina/PE/DVT/CABG ≤ 6 months, NYHA Class ≥ II, LVEF < 50%\n* Any gastrointestinal condition (e.g. malabsorption syndrome, surgical anastomosis, short bowel syndrome) that might affect the absorption of oral medications including the study drug",
        "miscellaneous_criteria": "Key"
    },
    "inclusion_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* High Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer - histologically or cytologically confirmed; metastatic or unresectable; platinum resistant (defined as recurrence within 6 months of platinum containing therapy) or platinum refractory; prior bevacizumab treatment, or ineligible or intolerant to bevacizumab, or did not receive bevacizumab based on Investigator judgement; if germline and/or somatic BRCA1/2 mutation, previously treated with PARP-inhibitor or ineligible or intolerant.",
            "criterions": [
                {
                    "exact_snippets": "High Grade Serous Ovarian Cancer, Fallopian Tube or Primary Peritoneal Cancer",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "High Grade Serous Ovarian Cancer",
                                "High Grade Serous Fallopian Tube Cancer",
                                "High Grade Serous Primary Peritoneal Cancer"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically or cytologically confirmed",
                    "criterion": "cancer diagnosis confirmation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically confirmed",
                                "cytologically confirmed"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic or unresectable",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "metastatic",
                                "unresectable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "platinum resistant (defined as recurrence within 6 months of platinum containing therapy) or platinum refractory",
                    "criterion": "platinum sensitivity",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "platinum resistant",
                                "platinum refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "prior bevacizumab treatment, or ineligible or intolerant to bevacizumab, or did not receive bevacizumab based on Investigator judgement",
                    "criterion": "bevacizumab treatment status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "prior treatment",
                                "ineligible",
                                "intolerant",
                                "not received based on Investigator judgement"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "if germline and/or somatic BRCA1/2 mutation, previously treated with PARP-inhibitor or ineligible or intolerant",
                    "criterion": "PARP-inhibitor treatment status in BRCA1/2 mutated patients",
                    "requirements": [
                        {
                            "requirement_type": "BRCA1/2 mutation status",
                            "expected_value": "germline and/or somatic mutation"
                        },
                        {
                            "requirement_type": "PARP-inhibitor treatment status",
                            "expected_value": [
                                "previously treated",
                                "ineligible",
                                "intolerant"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All Parts: Age ≥ 18 years, ECOG Performance Status ≤ 1, at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1, able to take oral medication without alteration",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "ECOG Performance Status ≤ 1",
                    "criterion": "ECOG Performance Status",
                    "requirements": [
                        {
                            "requirement_type": "maximum score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 1 site of measurable disease evaluable by CT scan or MRI per RECIST 1.1",
                    "criterion": "measurable disease site",
                    "requirements": [
                        {
                            "requirement_type": "minimum number of sites",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "site"
                            }
                        },
                        {
                            "requirement_type": "evaluable by imaging",
                            "expected_value": [
                                "CT scan",
                                "MRI"
                            ]
                        },
                        {
                            "requirement_type": "RECIST 1.1 criteria",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to take oral medication without alteration",
                    "criterion": "ability to take oral medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "without alteration",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Previously received KIF18A inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Previously received KIF18A inhibitor",
                    "criterion": "KIF18A inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* MSI-H, dMMR, POLE gene hotspot mutated, or known hypermutator phenotype",
            "criterions": [
                {
                    "exact_snippets": "MSI-H",
                    "criterion": "microsatellite instability status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "high"
                        }
                    ]
                },
                {
                    "exact_snippets": "dMMR",
                    "criterion": "mismatch repair status",
                    "requirements": [
                        {
                            "requirement_type": "deficiency",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "POLE gene hotspot mutated",
                    "criterion": "POLE gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "hotspot mutation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypermutator phenotype",
                    "criterion": "hypermutator phenotype",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cardiac parameters: MI or stroke ≤ 6 months, unstable angina/PE/DVT/CABG ≤ 6 months, NYHA Class ≥ II, LVEF < 50%",
            "criterions": [
                {
                    "exact_snippets": "MI or stroke ≤ 6 months",
                    "criterion": "history of myocardial infarction or stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina/PE/DVT/CABG ≤ 6 months",
                    "criterion": "history of unstable angina, pulmonary embolism, deep vein thrombosis, or coronary artery bypass graft",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "NYHA Class ≥ II",
                    "criterion": "NYHA heart failure class",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "LVEF < 50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any gastrointestinal condition (e.g. malabsorption syndrome, surgical anastomosis, short bowel syndrome) that might affect the absorption of oral medications including the study drug",
            "criterions": [
                {
                    "exact_snippets": "Any gastrointestinal condition (e.g. malabsorption syndrome, surgical anastomosis, short bowel syndrome) that might affect the absorption of oral medications including the study drug",
                    "criterion": "gastrointestinal condition",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effect on absorption of oral medications",
                            "expected_value": "might affect"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current CNS metastases or leptomeningeal disease",
            "criterions": [
                {
                    "exact_snippets": "Current CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "current_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Endometrioid, clear cell, mucinous, sarcomatoid, low-grade/borderline ovarian tumor or mixed tumors containing any of the above histologies",
            "criterions": [
                {
                    "exact_snippets": "Endometrioid",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "endometrioid"
                        }
                    ]
                },
                {
                    "exact_snippets": "clear cell",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "clear cell"
                        }
                    ]
                },
                {
                    "exact_snippets": "mucinous",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "mucinous"
                        }
                    ]
                },
                {
                    "exact_snippets": "sarcomatoid",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "sarcomatoid"
                        }
                    ]
                },
                {
                    "exact_snippets": "low-grade/borderline ovarian tumor",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": [
                                "low-grade ovarian tumor",
                                "borderline ovarian tumor"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "mixed tumors containing any of the above histologies",
                    "criterion": "tumor histology",
                    "requirements": [
                        {
                            "requirement_type": "histology type",
                            "expected_value": "mixed tumor containing any of the above histologies"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "Key",
            "criterions": [
                {
                    "exact_snippets": "Key",
                    "criterion": "key status",
                    "requirements": [
                        {
                            "requirement_type": "N/A",
                            "expected_value": "key"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}